# A Prospective, Single-center, Open-label Clinical Study to Evaluate the Safety and Efficacy of Inhaled BMD003(CFTR mRNA) in Chinese Adult Patients With Cystic Fibrosis

> **NCT06963008** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Cystic Fibrosis (CF)
- Gene Therapy

## Interventions

- **DRUG:** inhaled BMD003(CFTR mRNA)

## Key facts

- **NCT ID:** NCT06963008
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-10
- **Primary completion:** 2026-05-10
- **Final completion:** 2027-05-10
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06963008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06963008, "A Prospective, Single-center, Open-label Clinical Study to Evaluate the Safety and Efficacy of Inhaled BMD003(CFTR mRNA) in Chinese Adult Patients With Cystic Fibrosis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06963008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*